T1	control 0 10	Aprepitant
T2	intervention 18 31	dexamethasone
T3	condition 47 82	chemotherapy-induced delayed emesis
T4	eligibility 655 751	chemotherapy-naive patients with breast cancer treated with anthracyclines plus cyclophosphamide
T6	total-participants 1129 1132	580
T7	total-participants 1152 1155	551
T8	intervention-participants 1172 1175	273
T9	control-participants 1204 1207	278
T10	outcome 1229 1258	Day 1 complete response rates
T11	iv-bin-percent 1273 1278	87.6%
T12	cv-bin-percent 1301 1306	84.9%
T13	outcome 1338 1374	days 2 to 5, complete response rates
T15	outcome 1597 1619	Incidences of insomnia
T16	iv-bin-percent 1621 1625	2.9%
T17	cv-bin-percent 1628 1632	0.4%
T18	outcome 1647 1656	heartburn
T19	iv-bin-percent 1658 1662	8.1%
T20	cv-bin-percent 1665 1669	3.6%
T5	outcome-Measure 1025 1050	rate of complete response
T14	outcome 1486 1505	complete protection
T21	outcome 1507 1520	total control
T22	outcome 1522 1533	no vomiting
T23	outcome 1535 1544	no nausea
T24	outcome 1546 1585	score of Functional Living Index-Emesis
